1 |
J. S. Kim1, J. S.Lee, K. C. Im, S. J. Kim, S. Y. Kim, D. S. Lee, and D. H. Moon, "Performance measurement of the microPET focus 120 scanner", J Nucl Med, Vol.48, No.9, pp.1527-1535, 2007.
DOI
|
2 |
이원형, 정용안, "파킨슨병에서 18F-FDG PET의 임상이용", Nucl Med Mol Imaging, Vol.42, Supplement 1. 2008.
|
3 |
K. M. Kim, Establishment of Parkinson's Disease Model with MPTP in the Cynomolgus Monkey (Macaca fascicularis) [dissertation], University of Science and Technology, 2003.
|
4 |
A. L.. Rominger, E. Wagner, E. Mille, G. Boning, M. Esmaeilzadeh, B. Wangler, F. J. Gildehaus, S. Nowak, A. Bruche, K. Tatsch, P. Bartenstein, and P. Cumming, "Endogenous competition against binding of [(18)F]DMFP and [(18)F]fallypride to dopamine D(2/3) receptors in brain of living mouse", Synapse, Vol.64, No.4, pp.313-322, 2010.
DOI
ScienceOn
|
5 |
Y. L.. Fujimura, H. Ito, H. Takahashi, F. Yasuno, Y. Ikoma, M. R. Zhang, S. Nanko, K. Suzuki, and T. Suhara, "Measurement of dopamine D2 receptors in living human brain using 11C-raclopride with ultra-high specific radioactivity", Nucl Med Biol, Vol.37, No.7, pp.831-835, 2010.
DOI
ScienceOn
|
6 |
J. L. Mukherjee, Z. Y. Yang, M. K. Das, and T. Brown, "Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-18F-fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer", Nucl Med Biol, Vol.22, No.3, pp.283-296, 1995.
DOI
ScienceOn
|
7 |
M. Slifstein, D. R Hwang, Y. Huang, N. Guo, Y. Sudo, R. Narendran, P. Talbot, and M. Laruelle, "In vivo affinity of 18F-fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates," Psychopharmacology (Berl), Vol.175 No.3, pp.274-286, 2004.
DOI
|
8 |
C. Kohler, H. Hall, S. O. Ogren, and L. Gawell, "Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain", Biochem Pharmacol, Vol.34, No.13, pp.2251-2259, 1985.
DOI
ScienceOn
|
9 |
Mario Matarrese, Dmitri Soloviev, Sergio Todde, Felice Neutro, Pasquale Petta, Assunta Carpinelli, Michael Brussermann, and Marzia Galli Kienlecorrespondence Ferruccio Fazio., "Preparation of 11C- radioligands with high specific radioactivity on a commercial PET tracer synthesizer", Nucl Med Biol, Vol.30, No.1, pp.79-83, 2003.
DOI
ScienceOn
|
10 |
L. S. L. Kegeles, M. Slifstein, X. Xu, N. Urban, J. L. Thompson, T. Moadel, J. M. Harkavy-Friedman, R. Gil, M. Laruelle, and A. Abi-Dargham, "Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with 18F-fallypride positron emission tomography", Biol Psychiatry, Vol.68, No.7, pp.634-641, 2010.
DOI
ScienceOn
|
11 |
J. L. Noguchi, M. R. Zhang, K. Yanamoto, R. Nakao, and K. Suzuki, "In vitro binding of [(11)C]raclopride with ultrahigh specific activity in rat brain determined by homogenate assay and autoradiography", Nucl Med Biol, Vol.35, No.1, pp.19-27, 2008.
DOI
ScienceOn
|
12 |
안성민, 홍태기, 함준철, 김성철, "진단용 방사성 의약품의 정도관리", 한국콘텐츠학회논문지, Vol.9, No.11, 2009.
|
13 |
B. T. L. Christian, T. K. Narayanan, B. Shi, J. Mukherjee, "Quantitation of striatal and extrastriatal D-2 dopamine receptors using PET imaging of [(18)F]fallypride in nonhuman primates", Synapse, Vol.38, No.1, pp.71-79, 2000.
DOI
|
14 |
K. L. Ishibashi, K. Ishii, K. Oda, H. Mizusawa, and K. Ishiwata, "Competition between 11C-raclopride and endogenous dopamine in Parkinson's disease", Nucl Med Commun, Vol.31, No.2, pp.159-166, 2010.
DOI
ScienceOn
|